IN8bioINAB -0.45%24 Market Cap is $13.04 Mil as of Jun. 28, 2026. GuruFocus rates INAB with a GF Score™ of 24/100. Among 1,429 Biotechnology companies, IN8bio ranks worse than 81.95% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). IN8bio's share price for the quarter that ended in Mar. 2026 was $1.48. IN8bio's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 9.85 Mil. Therefore, IN8bio's market cap for the quarter that ended in Mar. 2026 was $14.57 Mil.
IN8bio's quarterly market cap
increased
from Sep. 2025 ($9.96 Mil) to Dec. 2025 ($22.85 Mil) but then
declined
from Dec. 2025 ($22.85 Mil) to Mar. 2026 ($14.57 Mil).
IN8bio's annual market cap
declined
from Dec. 2023 ($59.74 Mil) to Dec. 2024 ($18.64 Mil) but then
increased
from Dec. 2024 ($18.64 Mil) to Dec. 2025 ($22.85 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. IN8bio's Enterprise Value for Today is $-6.55 Mil.
IN8bio (NAS:INAB) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
IN8bio Market Cap Related Terms
IN8bio Market Cap Historical Data
* Premium members only.
The historical data trend for IN8bio's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, IN8bio's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
IN8bio Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, IN8bio's Market Cap distribution charts can be found below:
* The bar in red indicates where IN8bio's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
IN8bio's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IN8bio (INAB) has a Market Cap of $13.04 Mil as of Jun. 28, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on IN8bio and its competitors. According to the industry distribution chart, IN8bio ranks #1171 out of 1429 companies in the Biotechnology industry, placing it in the top 81.9%.
Is IN8bio's Market Cap too high?
IN8bio's current Market Cap is $13.04 Mil. The Biotechnology industry median Market Cap is 112.70. IN8bio's value of $13.04 Mil is 88.4% below this industry median. Based on the distribution chart, IN8bio ranks #1171 out of 1429 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, IN8bio has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does IN8bio's Market Cap compare to ZIVO and LPCN?
According to the Biotechnology industry distribution chart, IN8bio ranks #1171 out of 1429 companies for Market Cap. This places IN8bio in the lower half of its industry. The industry median Market Cap is 112.70. IN8bio's value of $13.04 Mil is 88.4% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 112.70, based on 1,429 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. IN8bio's current Market Cap of $13.04 Mil is 88.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on IN8bio and its competitors. For the Biotechnology industry, the median Market Cap is 112.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. IN8bio's current Market Cap is $13.04 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IN8bio stock overvalued right now?
IN8bio (INAB) has a current Market Cap of $13.04 Mil. The current Market Cap is $13.04 Mil and 88.4% below the Biotechnology industry median of 112.70. IN8bio's overall GF Score™ is 24/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For IN8bio (INAB), the current Market Cap is $13.04 Mil as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates and gamma-delta T cell engagers (TCEs) for cancer and autoimmune diseases. Gamma-delta T cells are a specialized population of T cells that possess properties. It has conducted two primary investigator-sponsored Phase 1 clinical trials evaluating its gamma-delta T cell technologies in cancer patients, which have both completed primary enrollment. INB-100 is assessing its DeltEx Allogeneic (Allo) gamma-delta T cell therapy in adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation (HSCT). It operates in a single segment.
24GF Score
Get the complete analysis for INAB
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
INAB has been successfully added to your 
